EUTOS长期生存评分在近期一组独立的“真实世界”慢性粒细胞白血病患者队列中的验证。 - Suppr

Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients.

作者信息

Geelen Inge G P, Sandin Fredrik, Thielen Noortje, Janssen Jeroen J W M, Hoogendoorn Mels, Visser Otto, Cornelissen Jan J, Hoglund Martin, Westerweel Peter E

机构信息

Department of Internal Medicine/Hematology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Regional Cancer Centre, Uppsala-Örebro, Sweden.

出版信息

Leukemia. 2018 Oct;32(10):2299-2303. doi: 10.1038/s41375-018-0136-7. Epub 2018 Apr 19.

DOI:10.1038/s41375-018-0136-7

PMID:29743721

Abstract

摘要

相似文献

Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients.

Leukemia. 2018 Oct;32(10):2299-2303. doi: 10.1038/s41375-018-0136-7. Epub 2018 Apr 19.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

J Cancer Res Clin Oncol. 2017 May;143(5):843-850. doi: 10.1007/s00432-016-2321-2. Epub 2017 Jan 12.

EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.

Hematology. 2013 Sep;18(5):247-52. doi: 10.1179/1607845412Y.0000000071. Epub 2013 Mar 20.

Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.

Turk J Haematol. 2017 Mar 1;34(1):10-15. doi: 10.4274/tjh.2016.0156. Epub 2016 Oct 18.

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.

Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261. Epub 2015 Sep 29.

Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?

Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):375-381. doi: 10.1016/j.clml.2017.02.029. Epub 2017 Mar 30.

Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):728-733. doi: 10.1016/j.clml.2017.06.009. Epub 2017 Jun 21.

Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.

Br J Haematol. 2016 Jun;173(6):945-6. doi: 10.1111/bjh.13649. Epub 2015 Aug 25.

Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.

Med Oncol. 2015 Aug;32(8):213. doi: 10.1007/s12032-015-0665-0. Epub 2015 Jul 5.

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.

Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3317-3320. doi: 10.31557/APJCP.2018.19.12.3317.

引用本文的文献

Prognostic scoring systems in chronic myeloid leukaemia.

Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15.

Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/: Selecting Optimal Treatment Based on Clinical and Molecular Findings.

Biomedicines. 2024 Oct 15;12(10):2339. doi: 10.3390/biomedicines12102339.

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.

Haematologica. 2024 Sep 1;109(9):2893-2907. doi: 10.3324/haematol.2023.284860.

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.

Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8.

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.

Cells. 2023 Jun 23;12(13):1703. doi: 10.3390/cells12131703.

Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.

Pharmacol Res Perspect. 2022 Oct;10(5):e01005. doi: 10.1002/prp2.1005.

[Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].

Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):54-62. doi: 10.3760/cma.j.issn.0253-2727.2022.01.011.

Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis.

Front Oncol. 2022 Feb 10;12:841546. doi: 10.3389/fonc.2022.841546. eCollection 2022.

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?

Cancers (Basel). 2021 Oct 12;13(20):5116. doi: 10.3390/cancers13205116.

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.

Front Oncol. 2021 Aug 26;11:739171. doi: 10.3389/fonc.2021.739171. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献